Aeterna Zentaris Appoints Olaf Althaus as General Manager and Managing Director of Aeterna Zentaris GmbH
May 31 2018 - 4:15PM
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS)
announced that Olaf Althaus has been appointed to the position of
General Manager and Managing Director of Aeterna Zentaris GmbH in
Frankfurt, Germany, effective June 1, 2018. Mr. Althaus has
over 17 years of executive experience in the pharmaceutical
industry and 10 years in investment banking. Mr. Althaus served as
Chief Executive Officer of CellMed AG, a biopharmaceutical company
he co-founded in 2000 and later merged into Biocompatibles
International plc (now BTG plc). Under his leadership, CellMed
developed numerous products in various indications, such as
diabetes type 2, intracerebral hemorrhage, aesthetics as well as
blood-diagnostics. Under Mr. Althaus’ leadership, CellMed AG
entered into several long-term product license agreements,
including with AstraZeneca, Fresenius, Merz Pharmaceuticals and
Terumo.
Before joining the pharmaceutical industry, Mr. Althaus worked
as an investment banker for international firms such as Dresdner
Kleinwort Wasserstein, Flemings and Pallas, primarily in corporate
finance and private equity. Mr. Althaus also served as
non-executive director for Deutsche Woolworth Holding GmbH from
2001 to 2008.
Mr. Althaus received a degree as Diplom Wirtschaftsingenieur
from Technische Universität (now Karlsruher Institut für
Technologie) in Karlsruhe.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. (the “Company”) is a specialty
biopharmaceutical company focused on developing Macrilen™
(macimorelin), an orally available ghrelin agonist, and making it
commercially available to patients with adult growth hormone
deficiency (AGHD). The Company has a license agreement with a
wholly-owned subsidiary of Strongbridge Biopharma plc to carry out
development, manufacturing, registration and commercialization of
Macrilen™ (macimorelin) in the United States and Canada. For
more information, visit www.zentaris.com.
Forward-Looking Statements This press release
contains forward-looking statements made pursuant to the
safe-harbor provisions of the U.S. Securities Litigation Reform Act
of 1995 and applicable Canadian securities laws, which reflect our
current expectations regarding future events. Forward-looking
statements may include, but are not limited to statements preceded
by, followed by, or that include the words "will," "expects,"
"believes," "intends," "would," "could," "may," "anticipates," and
similar terms that relate to future events, performance, or our
results. Forward-looking statements involve known risks and
uncertainties, many of which are discussed under the caption "Key
Information - Risk Factors" in our most recent Annual Report on
Form 20-F filed with the relevant Canadian securities regulatory
authorities in lieu of an annual information form and with the U.S.
Securities and Exchange Commission (“SEC"). Such risks and
uncertainties include, among others, our heavy dependence on
the success of Macrilen™ (macimorelin) and our reliance on third
parties for the manufacturing and commercialization of Macrilen™
(macimorelin), the importance of our licensing agreement with
Strongbridge and our ability to generate future out-license
agreements for Macrilen™ (macimorelin) in countries other than the
United States and Canada, and, more generally, uncertainties
related to the regulatory process for Macrilen™ (macimorelin) in
Europe and other jurisdictions outside of the United States, and
the degree of market acceptance of Macrilen™ (macimorelin).
Investors should consult the quarterly and annual filings of
Aeterna Zentaris with the applicable Canadian securities regulators
and the SEC for additional information on risks and uncertainties.
Given these uncertainties and risk factors, readers are cautioned
not to place undue reliance on these forward-looking statements. We
disclaim any obligation to update any such factors or to publicly
announce any revisions to any of the forward-looking statements
contained herein to reflect future results, events or developments,
unless required to do so by a governmental authority or applicable
law.
Contacts:
Aeterna Zentaris Inc. James Clavijo Chief Financial Officer
IR@aezsinc.com 305-304-7700
Reilly Connect Susan Reilly President
susan.reilly@reillyconnect.com 312-600-6783
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2023 to Jul 2024